Stockscreener 앱 받기
11.77
0.51%
0.06
시장 영업 전:
11.77
전일 마감가:
$11.71
열려 있는:
$11.75
하루 거래량:
309.65K
Relative Volume:
0.77
시가총액:
$232.90M
수익:
$244.06M
순이익/손실:
$87.01M
주가수익비율:
6.4624
EPS:
1.8213
순현금흐름:
$105.95M
1주 성능:
+3.52%
1개월 성능:
-1.92%
6개월 성능:
-24.79%
1년 성능:
-19.13%
1일 변동 폭
$11.45
$11.84
1주일 범위
$10.88
$12.07
52주 변동 폭
$10.41
$22.55
Keros Therapeutics Inc Stock (KROS) Company Profile
명칭
Keros Therapeutics Inc
전화
617-314-6297
주소
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Compare KROS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
11.77 | 232.90M | 244.06M | 87.01M | 105.95M | 1.8213 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-06-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-01-21 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2024-12-16 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-12-16 | 재확인 | Oppenheimer | Outperform |
| 2024-12-13 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-12 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-12-12 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-12-12 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | 개시 | Jefferies | Buy |
| 2024-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-09-23 | 개시 | Guggenheim | Buy |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-02-21 | 개시 | William Blair | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-07-31 | 개시 | Wedbush | Outperform |
| 2023-07-26 | 개시 | BofA Securities | Buy |
| 2023-02-14 | 개시 | Cowen | Outperform |
| 2022-10-18 | 개시 | Truist | Buy |
| 2022-07-26 | 개시 | BTIG Research | Buy |
| 2020-12-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-04 | 개시 | H.C. Wainwright | Buy |
| 2020-05-04 | 개시 | Jefferies | Buy |
| 2020-05-04 | 개시 | Piper Sandler | Overweight |
| 2020-05-04 | 개시 | SVB Leerink | Outperform |
모두보기
Keros Therapeutics Inc 주식(KROS)의 최신 뉴스
KROS stock: Does the Takeda deal lower dilution risk in 2026? - MSN
(KROS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Hold" by Analysts - MarketBeat
Sarcopenia Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | TNF Pharma, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross, Mirsc - Barchart
Insmed (INSM) soars 5.5%: Is further upside left in the stock? - MSN
Keros Therapeutics (KROS) to Release Quarterly Earnings on Tuesday - MarketBeat
Keros gains Orphan Drug designation for Duchenne muscular dystrophy asset - MSN
Responsive Playbooks and the KROS Inflection - Stock Traders Daily
KROS|Keros Therapeutics Inc|Price:11.510|Chg%:-0.05 - TradingKey
ADAR1 Capital Management urges Keros Therapeutics for board change - MSN
Why is Keros Therapeutics (KROS) up 2.5% since last earnings report? - MSN
Keros Therapeutics (KROS) Business Update | Q4 2025: Earnings UnderperformShared Buy Zones - Cổng thông tin điện tử tỉnh Lào Cai
[ARS] Keros Therapeutics, Inc. SEC Filing - Stock Titan
Keros Therapeutics (NASDAQ: KROS) focuses on rinvatercept and completes $375M capital return - Stock Titan
KROS SEC FilingsKeros Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
KROS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment - The Globe and Mail
KROS Rinvatercept: What to Know Before DMD Phase II Starts - Barchart
KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026? - TradingView
Keros Therapeutics (KROS) Stock: Growth vs Risks (Momentum Fading) 2026-04-20Verified Stock Signals - Cổng thông tin điện tử tỉnh Lào Cai
Bienaime buys Keros Therapeutics (KROS) shares worth $11,700 By Investing.com - Investing.com India
Insider Buying: Jean Bienaime Acquires Additional Shares of Keros Therapeutics Inc (KROS) - GuruFocus
Bienaime buys Keros Therapeutics (KROS) shares worth $11,700 - Investing.com
Keros Therapeutics (NASDAQ:KROS) Director Acquires $11,700.00 in Stock - MarketBeat
[Form 4] Keros Therapeutics, Inc. Insider Trading Activity - Stock Titan
Keros Therapeutics, Inc. (KROS) Stock Analysis: Exploring a Potential 92.59% Upside in the Biotech Industry - DirectorsTalk Interviews
Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Down 24.9% in March - MarketBeat
Understanding the Setup: (KROS) and Scalable Risk - Stock Traders Daily
Wall Street Recap: Can Keros Therapeutics Inc weather a recessionWeekly Gains Report & Risk Managed Investment Strategies - baoquankhu1.vn
Wedbush Maintains Keros Therapeutics (KROS) Neutral Recommendation - MSN
Is Keros Therapeutics (KROS) Stock Breaking Out | Price at $11.60, Down 7.13%Portfolio Management - UBND thành phố Hải Phòng
Is Keros Therapeutics (KROS) Stock heavily shorted | Price at $12.50, Up 2.12%Viral Momentum Stocks - Xã Thanh Hà
BlackRock (KROS) reports 1.99M-share, 10.1% passive stake in Keros Therapeutics - Stock Titan
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Rating of "Hold" from Analysts - MarketBeat
Keros Therapeutics (KROS) CEO exercises options for 55,000 shares - Stock Titan
JPMorgan Chase & Co. Raises Position in Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics, Inc. $KROS Shares Acquired by SG Americas Securities LLC - MarketBeat
Why Is Keros Therapeutics (KROS) Up 2.5% Since Last Earnings Report? - Yahoo Finance
The Technical Signals Behind (KROS) That Institutions Follow - Stock Traders Daily
Keros Therapeutics Inc (KROS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):